

# Gang Lin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9478198/publications.pdf>

Version: 2024-02-01

31  
papers

1,571  
citations

430874

18  
h-index

454955

30  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1527  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibitors selective for mycobacterial versus human proteasomes. <i>Nature</i> , 2009, 461, 621-626.	27.8	213
2	Selective Killing of Nonreplicating Mycobacteria. <i>Cell Host and Microbe</i> , 2008, 3, 137-145.	11.0	180
3	Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate. <i>Molecular Microbiology</i> , 2006, 59, 1417-1428.	2.5	120
4	Characterization of a Mycobacterium tuberculosis proteasomal ATPase homologue. <i>Molecular Microbiology</i> , 2004, 55, 561-571.	2.5	119
5	Stressed Mycobacteria Use the Chaperone ClpB to Sequester Irreversibly Oxidized Proteins Asymmetrically Within and Between Cells. <i>Cell Host and Microbe</i> , 2015, 17, 178-190.	11.0	104
6	Mycobacterium tuberculosis prcBA genes encode a gated proteasome with broad oligopeptide specificity. <i>Molecular Microbiology</i> , 2006, 59, 1405-1416.	2.5	98
7	Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E6863-E6870.	7.1	71
8	Structural Insights on the Mycobacterium tuberculosis Proteasomal ATPase Mpa. <i>Structure</i> , 2009, 17, 1377-1385.	3.3	65
9	Fellutamide B is a potent inhibitor of the Mycobacterium tuberculosis proteasome. <i>Archives of Biochemistry and Biophysics</i> , 2010, 501, 214-220.	3.0	57
10	N,C-Capped Dipeptides with Selectivity for Mycobacterial Proteasome over Human Proteasomes: Role of S3 and S1 Binding Pockets. <i>Journal of the American Chemical Society</i> , 2013, 135, 9968-9971.	13.7	54
11	Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E8425-E8432.	7.1	54
12	A philosophy of anti-infectives as a guide in the search for new drugs for tuberculosis. <i>Tuberculosis</i> , 2008, 88, S25-S33.	1.9	52
13	Distinct Specificities of Mycobacterium tuberculosis and Mammalian Proteasomes for N-Acetyl Tripeptide Substrates. <i>Journal of Biological Chemistry</i> , 2008, 283, 34423-34431.	3.4	51
14	Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes. <i>Nature Communications</i> , 2017, 8, 1692.	12.8	45
15	Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 405-410.	2.8	42
16	Structural basis for the assembly and gate closure mechanisms of the Mycobacterium tuberculosis 20S proteasome. <i>EMBO Journal</i> , 2010, 29, 2037-2047.	7.8	38
17	Improvement of Asparagine Ethylenediamines as Anti-malarial <i>Plasmodium</i> -Selective Proteasome Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6137-6145.	6.4	28
18	Immunoproteasome $\beta$ 5i $\alpha$ 1-Selective Dipeptidomimetic Inhibitors. <i>ChemMedChem</i> , 2016, 11, 2127-2131.	3.2	26

#	ARTICLE	IF	CITATIONS
19	Activity of Epigenetic Inhibitors against Plasmodium falciparum Asexual and Sexual Blood Stages. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	21
20	Development of a Highly Selective <i>Plasmodium falciparum</i> Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice. Angewandte Chemie - International Edition, 2021, 60, 9279-9283.	13.8	20
21	Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome. ACS Infectious Diseases, 2017, 3, 176-181.	3.8	19
22	Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the <i>Mycobacterium tuberculosis</i> Proteasome. Biochemistry, 2017, 56, 324-333.	2.5	14
23	Selective Phenylimidazole-Based Inhibitors of the <i>Mycobacterium tuberculosis</i> Proteasome. Journal of Medicinal Chemistry, 2019, 62, 9246-9253.	6.4	14
24	Microbial proteasomes as drug targets. PLoS Pathogens, 2021, 17, e1010058.	4.7	14
25	Immunoproteasome inhibitor DPLG3 attenuates experimental colitis by restraining NF- $\kappa$ B activation. Biochemical Pharmacology, 2020, 177, 113964.	4.4	13
26	Structure-Activity Relationships of Noncovalent Immunoproteasome $\beta$ 5i-Selective Dipeptides. Journal of Medicinal Chemistry, 2020, 63, 13103-13123.	6.4	10
27	Noncytotoxic Inhibition of the Immunoproteasome Regulates Human Immune Cells In Vitro and Suppresses Cutaneous Inflammation in the Mouse. Journal of Immunology, 2021, 206, 1631-1641.	0.8	9
28	Macrocyclic Peptides that Selectively Inhibit the <i>Mycobacterium tuberculosis</i> Proteasome. Journal of Medicinal Chemistry, 2021, 64, 6262-6272.	6.4	9
29	Design, Synthesis, and Optimization of Macrocyclic Peptides as Species-Selective Antimalaria Proteasome Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 9350-9375.	6.4	8
30	Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice. Angewandte Chemie, 2021, 133, 9365-9369.	2.0	2
31	Bacterial Proteasome. , 2013, , 3671-3677.		0